Biocom's program serves to extend effective, well-established and easy-to-perform self-collection nasal swab testing to over 1,300 members across the state under the Food and Drug Administration 's Emergency Use Authorization framework.
Test purchases come equipped with Everlywell Lens, a comprehensive reporting dashboard for human resource representatives, which gives organizations visibility into the status of individual kits, from registration to results.
The program with Everlywell will provide Biocom members access to rt-PCR tests that will determine the presence or absence of RNA from the SARS-CoV-2-virus.
Met with the highest standards of quality, safety, and reliability, Everlywell's straightforward sample collection, free shipping, and physician-reviewed results and insights ensure that we are connecting our members with one of the best testing solutions in the market.
The laboratories used by Everlywell are CLIA-certified and many are CAP-accredited, which means they must meet or exceed high precision, accuracy, and validity standards, obtain both state and federal certifications, and submit themselves to regular inspections as well as independent third-party performance verifications.
Biocom works on behalf of over 1,300 members to drive public policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge workforce development and STEM education programs, and create robust value-driven purchasing programs.
Biocom a public voice for research institutions and life science companies that fuel the California economy.
Biocom Purchasing Group offers member-driven strategic sourcing solutions. Biocom members save on average 15-25x their membership dues through the Biocom Purchasing Group.
In 2019, members collectively saved USD 280m and brought more ideas to market through a broad range of products, services and technologies offered by endorsed Purchasing Group suppliers.
Everlywell connects individuals to certified labs offering a suite of validated lab tests including Cholesterol, Heart Health, Fertility, STIs, Lyme Disease, Testosterone, Thyroid and more, including one of the only FDA-authorized at-home sample collection test kits for COVID-19 and the first at-home sample collection test kits for fertility, high-risk HPV, and indoor and outdoor allergies.
Prices start at USD 49 and tests are generally covered by Flexible Spending and Health Savings Accounts.
The Austin-based company was founded in 2015 and is advised by a Scientific advisory board that includes some of the nation's top scientists from Harvard, MIT, Google and NYU. Everlywell was selected as one of Fast company's Most Innovative Companies in 2019.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients